Abbott Laboratories: What's Behind The Q2 Earnings Slump?

Abbott Laboratories (ABT) stock plummeted 8.5% after its Q2 earnings, erasing its year-to-date outperformance. While Q2 sales of $11.14B surpassed estimates and non-GAAP EPS met expectations, the decline was primarily driven by a significant reduction in FY25 organic sales growth guidance from 8% to 6.5%. This revision, largely due to diminishing COVID-19 diagnostic test demand and the impact of China's Volume-Based Procurement (VBP) programs on Core Lab Diagnostics, also included a slight operating margin guidance cut. The market reacted sharply to the lowered outlook and ABT's projected 10.3% FY EPS growth, which lags the broader healthcare equipment industry's 13.5% average, evidenced by the stock closing below its 200-day moving average on high volume.

Analysis

Abbott Laboratories (ABT) experienced a significant 8.5% stock decline, erasing its year-to-date outperformance against the S&P 500 and its healthcare peers. This sharp, high-volume move, the largest since June 2021, was triggered by a disappointing full-year outlook despite a mixed Q2 performance. While Q2 reported sales of $11.14 billion beat estimates and marked the highest YoY growth in 12 quarters at 7.4%, the non-GAAP EPS of $1.26 merely met expectations, breaking a multi-year trend of significant earnings beats. The primary catalyst for the sell-off was the downward revision of FY25 guidance. The company cut its organic sales growth forecast from 8% to 6.5%, citing a $700 million adverse impact from declining COVID-19 test demand and China's Volume-Based Procurement (VBP) policy, which is pressuring its Core Lab Diagnostics business. Furthermore, the operating margin guidance was reduced by 25bps, implying a weaker second half, and Q3 EPS guidance suggests a slowdown to single-digit growth. Although the full-year adjusted EPS target of $5.15 remains, the implied 10.3% growth lags the healthcare equipment industry's 13.5% average. The negative sentiment was amplified by the stock decisively breaking below its 200-day moving average for the first time in nearly a year on 4x average volume, a significant bearish technical signal.

Key Decisions for Investors

• Given the lowered guidance and the significant technical breakdown below the 200-day moving average on high volume, investors should exercise caution as momentum has clearly shifted to the downside.
• Monitor the performance of the Diagnostics segment closely, particularly the impact from China's VBP policy and the rate of decline in COVID-related sales, as these are the core drivers of the revised, weaker outlook.
• While the stock's full-year EPS guidance remains intact, investors must assess if the projected 10.3% growth justifies a 23.4x forward P/E multiple, especially as this growth rate now trails the industry average.
• Potential long-term buyers may consider waiting for the stock to test the $113 level, which represents a confluence of a prior support zone and the lower boundary of its multi-year ascending channel, before initiating new positions.